sodium succinate
Approved
Nov 16, 1971
Succinic acid is a dicarboxylic acid, which has multiple biological roles as a metabolic intermediate being converted into fumarate by the enzyme succinate dehydrogenase in complex 2 of the electron transport chain which is involved in making ATP, and as a signaling molecule reflecting the cellular metabolic state. Succinate is generated in mitochondria via the tricarboxylic acid cycle (TCA), an energy-yielding process shared by all organisms. Succinate can exit the mitochondrial matrix and function in the cytoplasm as well as the extracellular space, changing gene expression patterns, modulating epigenetic landscape or demonstrating hormone-like signaling. Dysregulation of succinate synthesis, and therefore ATP synthesis, happens in some genetic mitochondrial diseases, such as Leigh's disease, and Mela's disease and degradation can lead to pathological conditions, such as malignant transformation, inflammation and tissue injury. Succinic acid is a precursor to some polyesters and a component of some alkyd resins. Succinic acid also serves as the bases of certain biodegradable polymers, which are of interest in tissue engineering applications. As a food additive and dietary supplement, succinic acid is generally recognized as safe by the U.S. Food and Drug Administration. Succinic acid is used primarily as an acidity regulator in the food and beverage industry. It is also available as a flavoring agent, contributing a somewhat sour and astringent component to umami taste.[11] As an excipient in pharmaceutical products, it is also used to control acidity or as a counter ion. Drugs involving succinate include metoprolol succinate, sumatriptan succinate, Doxylamine succinate or solifenacin succinate. — NCATS
Clinical trial activity
10 trials · 29 clinical orgs · 1 marketing orgs
Earliest trial started Jun 1, 2016 (NCT02930161)
Timeline
1970s
- Nov 16, 1971
Earliest FDA Approval
- Nov 16, 1971
Elkins Sinn — Marketing Organization
Indications
Approved for
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Approval history
- approvedNov 16, 1971
Chemistry & pharmacology
SMILES
OC(=O)CCC(O)=O- Mol. weight
- 118.088 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaSuccinic acid ↗
- NCATSAB6MNQ6J6L ↗
- ChEMBLCHEMBL576 ↗
- ChEMBLCHEMBL1200345 ↗
Also known as
- butanedioic acid
- butanedioic acid
- butanedioic acid
- butanedioic acid
- butanedioic acid
- runihol
- sodium succinate
- sodium succinate
- sodium succinate
- succinic acid
- succinic acid
- succinic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06183242 | Phase 2/Phase 3 (Phase 3) | May 27, 2023 | Polysan, Ltd. |
| NCT05935787 | Phase 3 | Mar 23, 2023 | Polysan, Ltd. |
| NCT04631484 | Phase 3 | Oct 8, 2020 | Polysan, Ltd. |
| NCT04649203 | Phase 3 | Jun 29, 2020 | Polysan, Ltd. |
| NCT04134403 | Phase 3 | Dec 1, 2019 | Baqiyatallah Medical Sciences University, East Carolina University, Hamadan University of Medical Science, University of Tehran |
| NCT03401398 | Phase 3 | Jan 2, 2019 | Canadian Critical Care Trials Group, Canadian Institutes of Health Research (CIHR), Harvard University, National Institutes of Health (NIH), University of Cincinnati, University of Ottawa, University of Washington |
| NCT03849664 | Phase 3 | Jun 2, 2017 | Polysan, Ltd., St. Petersburg Research Institute of Emergency Medicine |
| NCT03418935 | Phase 3 | Apr 3, 2017 | BioEq, Irkutsk Regional Clinical Hospital, Leningrad Regional Clinical Hospital, Polysan, Ltd., State Budgetary Health Care Institution "City Hospital № 26", St. Petersburg Mechnikov State Medical Academy |
| NCT03416062 | Phase 3 | Apr 3, 2017 | Avicenna Medical Center, BioEq, Irkutsk Regional Clinical Hospital, Petrov Research Institute of Oncology, Polysan, Ltd., Regional Clinical oncologic center, Omsk region, State Budgetary Health Care Institution "City Hospital № 26", St. Petersburg Mechnikov State Medical Academy |
| NCT02930161 | Phase 2 | Jun 1, 2016 | BioEq, Government of Russia, Hepatologist Ltd., Military Medical Academy named after SM Kirov, the Russian Ministry of Defense, Hospital Therapeutic Department and Clinic, Moscow State University, Polysan, Ltd., Russian Military, State Novosibirsk Regional Clinical Hospital, St. Petersburg City Hospital of the Holy Martyr Elizabeth, St. Petersburg State Public Medical Institution |
Organizations
Research & Development (29)
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Elkins Sinn | For profit | MKTG | Nov 16, 1971 |